204 related articles for article (PubMed ID: 26694905)
1. The Dose-Response Relationship of bacillus Calmette-Guérin and Urothelial Carcinoma Cell Biology.
Shah G; Zhang G; Chen F; Cao Y; Kalyanaraman B; See WA
J Urol; 2016 Jun; 195(6):1903-10. PubMed ID: 26694905
[TBL] [Abstract][Full Text] [Related]
2. Loss of bacillus Calmette-Guérin viability adversely affects the direct response of urothelial carcinoma cells to bacillus Calmette-Guérin exposure.
Shah G; Zhang G; Chen F; Cao Y; Kalyanaraman B; See W
J Urol; 2014 Mar; 191(3):823-9. PubMed ID: 24035882
[TBL] [Abstract][Full Text] [Related]
3. MB49 murine urothelial carcinoma: molecular and phenotypic comparison to human cell lines as a model of the direct tumor response to bacillus Calmette-Guerin.
Chen F; Zhang G; Cao Y; Hessner MJ; See WA
J Urol; 2009 Dec; 182(6):2932-7. PubMed ID: 19853870
[TBL] [Abstract][Full Text] [Related]
4. HMGB1 release by urothelial carcinoma cells in response to Bacillus Calmette-Guérin functions as a paracrine factor to potentiate the direct cellular effects of Bacillus Calmette-Guérin.
Zhang G; Chen F; Cao Y; Amos JV; Shah G; See WA
J Urol; 2013 Sep; 190(3):1076-82. PubMed ID: 23353043
[TBL] [Abstract][Full Text] [Related]
5. HMGB1 release by urothelial carcinoma cells is required for the in vivo antitumor response to Bacillus Calmette-Guérin.
Zhang G; Chen F; Cao Y; Johnson B; See WA
J Urol; 2013 Apr; 189(4):1541-6. PubMed ID: 23041342
[TBL] [Abstract][Full Text] [Related]
6. Contributors to HMGB1 release by urothelial carcinoma cells in response to bacillus Calmette-Guérin.
Zhang G; Chen F; Cao Y; See WA
J Urol; 2013 Oct; 190(4):1398-403. PubMed ID: 23583857
[TBL] [Abstract][Full Text] [Related]
7. H2O2 generation by bacillus Calmette-Guérin induces the cellular oxidative stress response required for bacillus Calmette-Guérin direct effects on urothelial carcinoma biology.
Shah G; Zielonka J; Chen F; Zhang G; Cao Y; Kalyanaraman B; See W
J Urol; 2014 Oct; 192(4):1238-48. PubMed ID: 24928267
[TBL] [Abstract][Full Text] [Related]
8. Bacillus Calmette-Guerin inhibits apoptosis in human urothelial carcinoma cell lines in response to cytotoxic injury.
Chen F; Zhang G; Cao Y; Payne R; See WA
J Urol; 2007 Nov; 178(5):2166-70. PubMed ID: 17870116
[TBL] [Abstract][Full Text] [Related]
9. Randomized Controlled Study of the Efficacy, Safety and Quality of Life with Low Dose bacillus Calmette-Guérin Instillation Therapy for Nonmuscle Invasive Bladder Cancer.
Yokomizo A; Kanimoto Y; Okamura T; Ozono S; Koga H; Iwamura M; Tanaka H; Takahashi S; Tsushima T; Kanayama HO; Akaza H; Shinohara N; Mugiya S; Nomata K; Nakamura T; Naito S
J Urol; 2016 Jan; 195(1):41-6. PubMed ID: 26307162
[TBL] [Abstract][Full Text] [Related]
10. Long term protection in bladder cancer following intralesional immunotherapy.
Reichert DF; Lamm DL
J Urol; 1984 Sep; 132(3):570-3. PubMed ID: 6381762
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer.
Dinney CP; Fisher MB; Navai N; O'Donnell MA; Cutler D; Abraham A; Young S; Hutchins B; Caceres M; Kishnani N; Sode G; Cullen C; Zhang G; Grossman HB; Kamat AM; Gonzales M; Kincaid M; Ainslie N; Maneval DC; Wszolek MF; Benedict WF
J Urol; 2013 Sep; 190(3):850-6. PubMed ID: 23507396
[TBL] [Abstract][Full Text] [Related]
12. Intravesical bacillus Calmette-Guérin efficiently reduces p70S6K1 but not 4E-BP1 phosphorylation in nonmuscle invasive bladder cancer.
Ferrari KL; de Camargo JA; Rocha GZ; Carvalheira JB; Saad MJ; Billis A; Reis LO
J Urol; 2015 Feb; 193(2):682-9. PubMed ID: 25200808
[TBL] [Abstract][Full Text] [Related]
13. The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.
Gontero P; Oderda M; Mehnert A; Gurioli A; Marson F; Lucca I; Rink M; Schmid M; Kluth LA; Pappagallo G; Sogni F; Sanguedolce F; Schiavina R; Martorana G; Shariat SF; Chun F
J Urol; 2013 Sep; 190(3):857-62. PubMed ID: 23545101
[TBL] [Abstract][Full Text] [Related]
14. A synthetic polyvalent ligand for α5β1 integrin activates components of the urothelial carcinoma cell response to bacillus Calmette-Guérin.
Chen F; Zhang G; Cao Y; Wakim B; See WA
J Urol; 2013 Mar; 189(3):1104-9. PubMed ID: 22999999
[TBL] [Abstract][Full Text] [Related]
15. Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors.
Hudson MA; Yuan JJ; Catalona WJ; Ratliff TL
J Urol; 1990 Dec; 144(6):1362-4. PubMed ID: 2231927
[TBL] [Abstract][Full Text] [Related]
16. Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer.
Nepple KG; Lightfoot AJ; Rosevear HM; O'Donnell MA; Lamm DL;
J Urol; 2010 Nov; 184(5):1915-9. PubMed ID: 20846688
[TBL] [Abstract][Full Text] [Related]
17. Do bacteriostatic urethral lubricants affect the clinical efficacy of intravesical bacillus Calmette-Guérin therapy?
Loertzer H; Brake M; Horsch R; Keller H
Urology; 2001 May; 57(5):900-5. PubMed ID: 11337290
[TBL] [Abstract][Full Text] [Related]
18. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study.
Yutkin V; Pode D; Pikarsky E; Mandelboim O
J Urol; 2007 Dec; 178(6):2660-4. PubMed ID: 17945285
[TBL] [Abstract][Full Text] [Related]
19. Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results.
Kelley DR; Ratliff TL; Catalona WJ; Shapiro A; Lage JM; Bauer WC; Haaff EO; Dresner SM
J Urol; 1985 Jul; 134(1):48-53. PubMed ID: 3892051
[TBL] [Abstract][Full Text] [Related]
20. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
